TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Corvus Pharmaceuticals ( (CRVS) ) has provided an update.
On June 12, 2025, Corvus Pharmaceuticals held its Annual Meeting of Stockholders, where key decisions were made regarding the company’s governance and operations. Stockholders elected Class III directors, ratified the selection of PricewaterhouseCoopers LLC as the independent accounting firm, and approved executive compensation, reflecting continued support for the company’s strategic direction.
The most recent analyst rating on (CRVS) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Corvus Pharmaceuticals stock, see the CRVS Stock Forecast page.
Spark’s Take on CRVS Stock
According to Spark, TipRanks’ AI Analyst, CRVS is a Neutral.
Corvus Pharmaceuticals exhibits significant financial difficulties with no revenue and increasing losses. Technical indicators show a bearish trend, and valuation metrics are weak. However, clinical advancements and strategic governance changes provide some optimism. Overall, the stock is rated at the lower end of the scale due to its financial challenges and negative technical trends, with potential upside from clinical developments.
To see Spark’s full report on CRVS stock, click here.
More about Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc. operates in the biotechnology industry, focusing on the development and commercialization of innovative immunotherapy treatments for cancer and other serious diseases.
Average Trading Volume: 1,048,594
Technical Sentiment Signal: Buy
Current Market Cap: $347M
Find detailed analytics on CRVS stock on TipRanks’ Stock Analysis page.